- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.01. | Medicus Pharma Ltd: Medicus Pharma Marks Nasdaq Anniversary With Opening Bell Ceremony | 830 | ACCESS Newswire | PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 23, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided biotech/life sciences company focused on advancing... ► Artikel lesen | |
| 22.01. | Medicus Pharma Ltd. Announces Amendment to LifeArc License Improving Teverelix Long-Term Economic and Development Profile | 1 | GlobeNewswire (USA) | ||
| 20.01. | Medicus Pharma Ltd. Celebrates One Year on Nasdaq with Opening Bell Ceremony on January 22, 2026 | 1 | GlobeNewswire (USA) | ||
| 05.01. | Medicus Pharma to present phase 2 data at Biotech Showcase 2026 | 2 | Investing.com | ||
| 05.01. | Medicus Pharma Ltd. to Present at Biotech Showcase 2026 as SkinJect Phase 2 Clinical Data Approaches Readout and Partnering Readiness Accelerates | 2 | GlobeNewswire (USA) | ||
| MEDICUS PHARMA Aktie jetzt für 0€ handeln | |||||
| 30.12.25 | Medicus Pharma startet "At-the-Market"-Eigenkapitalprogramm über bis zu 15,3 Mio. US-Dollar | 1 | Investing.com Deutsch | ||
| 30.12.25 | Medicus Pharma Ltd. - 8-K, Current Report | - | SEC Filings | ||
| 22.12.25 | Medicus Pharma Ltd. Announces Engagement With Reliant AI to Develop Artificial Intelligence Driven Clinical Data Analytics Platform | 570 | ACCESS Newswire | The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute urinary... ► Artikel lesen | |
| 17.12.25 | Medicus Pharma completes patient enrolment for basal cell carcinoma trial | 1 | PMLiVE | ||
| 15.12.25 | Medicus Pharma Ltd. Completes Enrolment of Ninety (90) Patients for Phase 2 Clinical Study (SKNJCT-003) to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin | 196 | GlobeNewswire (Europe) | THE COMPANY EXPECTS TO RELEASE TOPLINE RESULTS FOR SKNJCT-003 PHASE 2 CLINICAL TRIAL BEFORE THE END OF Q1 2026 AND REQUEST END-OF-PHASE 2 (EOP2) WITH THE FOOD AND DRUG ADMINISTRATION (FDA) IN H1 2026... ► Artikel lesen | |
| 08.12.25 | Medicus Pharma Ltd. - 8-K, Current Report | - | SEC Filings | ||
| 05.12.25 | Medicus Pharma sichert sich 5,1 Mio. US-Dollar durch Optionsschein-Vereinbarung | 2 | Investing.com Deutsch | ||
| 05.12.25 | Medicus Pharma secures $5.1 million from warrant exercise agreement | 1 | Investing.com | ||
| 05.12.25 | Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement | 384 | ACCESS Newswire | Maxim Group LLC is acting as the exclusive Financial Advisor for the transaction PHILADELPHIA, PA / ACCESS Newswire / December 5, 2025 / Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company")... ► Artikel lesen | |
| 01.12.25 | Medicus Pharma Appoints President Carolyn Bonner CFO | 3 | RTTNews | ||
| 01.12.25 | Medicus Pharma appoints Carolyn Bonner as president and CFO | 1 | Investing.com | ||
| 01.12.25 | Medicus Pharma appoints Carolyn Bonner as CFO after Quinlan resigns | 1 | Investing.com | ||
| 01.12.25 | Medicus Pharma Ltd. Appoints Carolyn Bonner as Chief Financial Officer in Addition to Her Role as President | 265 | ACCESS Newswire | Carolyn Bonner Succeeds James ('Jim') Quinlan Who Has Resigned for Health Reasons After Taking Medical Leave in September 2025 PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / December 1, 2025 / Medicus... ► Artikel lesen | |
| 01.12.25 | Doppelrolle bei Medicus Pharma: Carolyn Bonner wird Präsidentin und CFO | - | Investing.com Deutsch | ||
| 01.12.25 | Medicus Pharma ernennt Präsidentin Carolyn Bonner zur neuen Finanzchefin | - | Investing.com Deutsch |
1 2 3 4 Weiter >>
75 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 23,015 | -0,07 % | Ihre wichtigsten Termine: Frische Quartalszahlen von: Pepsico, PayPal, Pfizer, AMD, Merck & Co und KSB | © Foto: Jeff Chiu/AP/dpaGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 07:00... ► Artikel lesen | |
| GILEAD SCIENCES | 128,98 | -0,05 % | Gilead wins favorable U.S. label update for Yescarta | ||
| ELI LILLY | 894,80 | -0,01 % | Abnehmpille schlägt ein: Starker Start ins neue Jahr - Novo Nordisk zeigt Eli Lilly die Rücklichter! | © Foto: Kristian Tuxen Ladegaard Berg - NurPhotoNach einem schwachen Vorjahr meldet sich Novo Nordisk 2026 eindrucksvoll zurück. Die neue Wegovy-Tablette sorgt in den USA für einen starken Marktstart.... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 402,50 | -0,45 % | WuXi Biologics Jumps On Pact With Vertex Pharma For T-Cell Engager In Autoimmune Disease | CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - WuXi Biologics (2269. HK,WXIBF), a Contract Research, Development, and Manufacturing Organisation, announced on Tuesday that it has signed a license and... ► Artikel lesen | |
| EYEPOINT | 11,035 | 0,00 % | RBC Capital reiterates Outperform rating on EyePoint stock amid recent decline | ||
| JAZZ PHARMACEUTICALS | 139,35 | -0,46 % | Boehringer Ingelheim Limited: Boehringer Ingelheim announces clinical collaboration with Jazz Pharmaceuticals to advance HER2-targeted therapy in breast cancer | Phase 1b study to evaluate combination of zongertinib and zanidatamab in HER2-positive breast cancer patients
Ingelheim, Germany- 12 January, 2026 - Boehringer Ingelheim today announced a strategic... ► Artikel lesen | |
| LIGAND PHARMACEUTICALS | 160,00 | 0,00 % | Ligand Pharmaceuticals: Ligand Partner SQ Innovation Receives FDA Approval for Lasix ONYU, an At-Home Treatment for Edema in Heart Failure Patients | Second-generation delivery device offers cost-effective alternative to hospital care benefiting patients, providers, and payors Lasix ONYU is the 17th Captisol-enabled approved product JUPITER, Fla.... ► Artikel lesen | |
| OPKO HEALTH | 1,046 | 0,00 % | OPKO Health, Inc.: OPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with Hypoparathyroidism | This is the third program that successfully combines Entera's oral peptide N-Tab- platform with OPKO's advanced protein chemistry capabilities The companies have accelerated this program and aim... ► Artikel lesen | |
| UNITED THERAPEUTICS | 410,20 | -0,15 % | United Therapeutics Corporation to Present at Upcoming Investor Conferences | United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that company executives will provide an overview and update on the company during fireside chat sessions... ► Artikel lesen | |
| ROYALTY PHARMA | 37,580 | -0,53 % | Royalty Pharma And Teva Broaden Collaboration To Advance Potential Vitiligo Treatment | WASHINGTON (dpa-AFX) - Royalty Pharma plc. (RPRX) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (TEVA), have announced a funding agreement of up to $500 million... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 20,550 | -0,63 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update | Reported Q3 2025 Total Revenues of $148.4 Million, Driven by Continued FIRDAPSE® Growth, Strong AGAMREE® Uptake and Growth, and Continued Demand for FYCOMPA® Raising Full-Year 2025 Total Revenue Guidance... ► Artikel lesen | |
| TG THERAPEUTICS | 24,365 | 0,00 % | TG Therapeutics presents BRIUMVI data at ACTRIMS forum | ||
| BRIDGEBIO PHARMA | 57,98 | +0,73 % | BridgeBio shares slide amid report that Pfizer will withdraw Vyndamax EU patent | ||
| AVADEL PHARMACEUTICALS | 18,100 | 0,00 % | Avadel Pharmaceuticals plc: Avadel Pharmaceuticals Announces that Avadel Shareholders Approve the Proposed Acquisition by Alkermes | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.... ► Artikel lesen | |
| CORBUS PHARMACEUTICALS | 6,450 | -2,27 % | Corbus Pharmaceuticals Holdings, Inc.: Corbus Pharmaceuticals Reports Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss | CRB-913 was safe and well-tolerated across all doses studiedDaily neuropsychiatric assessments using CSSRS, PHQ-9, and GAD-7 were negative for all participantsA placebo-adjusted mean weight loss of... ► Artikel lesen |
Das Unternehmen MEDICUS PHARMA LTD kann der Branche Pharma zugeordnet werden. Die relative Kursveränderung beträgt aktuell +1,83 % bei einem Aktienkurs von 1,110 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MEDICUS PHARMA LTD finden Sie auf Wallstreet Online.